Revenues of PLUS THERAPEUTICS, INC. from 30 Jun 2010 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary: PLUS THERAPEUTICS, INC. quarterly and annual Revenues in USD history and change rate from 30 Jun 2010 to 30 Sep 2025.
PLUS THERAPEUTICS, INC. Revenues for the quarter ending 30 Sep 2025 was $1,397,000, a 4.1% decline year-over-year.
PLUS THERAPEUTICS, INC. Revenues for the twelve months ending 30 Sep 2025 was $5,258,000.
PLUS THERAPEUTICS, INC. annual Revenues for 2024 was $5,824,000, a 19% increase from 2023.
PLUS THERAPEUTICS, INC. annual Revenues for 2023 was $4,913,000.
PLUS THERAPEUTICS, INC. annual Revenues for 2017 was $2,689,000, a 42% decline from 2016.
Source SEC data: View on sec.gov

Revenues, Trailing 12 Months (USD)

Revenues, Quarterly (USD)

Revenues, YoY Quarterly Change (%)

Revenues, Annual (USD)

Revenues, YoY Annual Change (%)

PLUS THERAPEUTICS, INC. Quarterly Revenues (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$5,258,000	$1,397,000	-$59,000	-4.1%	01 Jul 2025	30 Sep 2025	10-Q	30 Oct 2025	2025	Q3
Q2 2025	$5,317,000	$1,390,000	+$111,000	+8.7%	01 Apr 2025	30 Jun 2025	10-Q	14 Aug 2025	2025	Q2
Q1 2025	$5,206,000	$1,059,000	-$618,000	-37%	01 Jan 2025	31 Mar 2025	10-Q	30 May 2025	2025	Q1
Q4 2024	$5,824,000	$1,412,000			01 Oct 2024	31 Dec 2024	10-K	31 Mar 2025	2024	FY
Q3 2024		$1,456,000			01 Jul 2024	30 Sep 2024	10-Q	30 Oct 2025	2025	Q3
Q2 2024		$1,279,000			01 Apr 2024	30 Jun 2024	10-Q	14 Aug 2025	2025	Q2
Q1 2024		$1,677,000			01 Jan 2024	31 Mar 2024	10-Q	30 May 2025	2025	Q1
Q2 2018	$2,520,000	$660,000	-$309,000	-32%	01 Apr 2018	30 Jun 2018	10-Q	14 Aug 2018	2018	Q2
Q1 2018	$2,829,000	$731,000	+$140,000	+24%	01 Jan 2018	31 Mar 2018	10-Q	11 May 2018	2018	Q1
Q4 2017	$2,689,000	$662,000	-$804,000	-55%	01 Oct 2017	31 Dec 2017	10-K	09 Mar 2018	2017	FY
Q3 2017	$3,493,000	$467,000	-$264,000	-36%	01 Jul 2017	30 Sep 2017	10-K	09 Mar 2018	2017	FY
Q2 2017	$3,757,000	$969,000	-$157,000	-14%	01 Apr 2017	30 Jun 2017	10-Q	14 Aug 2018	2018	Q2
Q1 2017	$3,914,000	$591,000	-$742,000	-56%	01 Jan 2017	31 Mar 2017	10-Q	11 May 2018	2018	Q1
Q4 2016	$4,656,000	$1,466,000	-$90,000	-5.8%	01 Oct 2016	31 Dec 2016	10-K	09 Mar 2018	2017	FY
Q3 2016	$4,746,000	$731,000	-$35,000	-4.6%	01 Jul 2016	30 Sep 2016	10-K	09 Mar 2018	2017	FY
Q2 2016	$4,781,000	$1,126,000	-$488,000	-30%	01 Apr 2016	30 Jun 2016	10-K	09 Mar 2018	2017	FY
Q1 2016	$5,269,000	$1,333,000	+$431,000	+48%	01 Jan 2016	31 Mar 2016	10-K	09 Mar 2018	2017	FY
Q4 2015	$4,838,000	$1,556,000	-$913,000	-37%	01 Oct 2015	31 Dec 2015	10-K	24 Mar 2017	2016	FY
Q3 2015	$5,751,000	$766,000	+$248,000	+48%	01 Jul 2015	30 Sep 2015	10-K	24 Mar 2017	2016	FY
Q2 2015	$5,503,000	$1,614,000	+$679,000	+73%	01 Apr 2015	30 Jun 2015	10-K	24 Mar 2017	2016	FY
Q1 2015	$4,824,000	$902,000	-$129,000	-13%	01 Jan 2015	31 Mar 2015	10-K	24 Mar 2017	2016	FY
Q4 2014	$4,953,000	$2,469,000	-$237,000	-8.8%	01 Oct 2014	31 Dec 2014	10-K	11 Mar 2016	2015	FY
Q3 2014	$5,190,000	$518,000	-$1,098,000	-68%	01 Jul 2014	30 Sep 2014	10-K	11 Mar 2016	2015	FY
Q2 2014	$6,288,000	$935,000	-$473,000	-34%	01 Apr 2014	30 Jun 2014	10-K	11 Mar 2016	2015	FY
Q1 2014	$6,761,000	$1,031,000	-$361,000	-26%	01 Jan 2014	31 Mar 2014	10-K	11 Mar 2016	2015	FY
Q4 2013	$7,122,000	$2,706,000	-$1,261,000	-32%	01 Oct 2013	31 Dec 2013	10-K	16 Mar 2015	2014	FY
Q3 2013	$8,383,000	$1,616,000	+$302,000	+23%	01 Jul 2013	30 Sep 2013	10-K	16 Mar 2015	2014	FY
Q2 2013	$8,081,000	$1,408,000	-$539,000	-28%	01 Apr 2013	30 Jun 2013	10-K	16 Mar 2015	2014	FY
Q1 2013	$8,620,000	$1,392,000	-$89,000	-6%	01 Jan 2013	31 Mar 2013	10-K	16 Mar 2015	2014	FY
Q4 2012	$8,709,000	$3,967,000	+$1,891,000	+91%	01 Oct 2012	31 Dec 2012	10-K	14 Mar 2014	2013	FY
Q3 2012	$6,818,000	$1,314,000	-$820,000	-38%	01 Jul 2012	30 Sep 2012	10-K	14 Mar 2014	2013	FY
Q2 2012	$7,638,000	$1,947,000	-$464,000	-19%	01 Apr 2012	30 Jun 2012	10-K	14 Mar 2014	2013	FY
Q1 2012	$8,102,000	$1,481,000	+$119,000	+8.7%	01 Jan 2012	31 Mar 2012	10-K	14 Mar 2014	2013	FY
Q4 2011	$7,983,000	$2,076,000			01 Oct 2011	31 Dec 2011	10-K	15 Mar 2013	2012	FY
Q3 2011		$2,134,000	+$615,000	+40%	01 Jul 2011	30 Sep 2011	10-K	15 Mar 2013	2012	FY
Q2 2011		$2,411,000	+$320,000	+15%	01 Apr 2011	30 Jun 2011	10-K	15 Mar 2013	2012	FY
Q1 2011		$1,362,000			01 Jan 2011	31 Mar 2011	10-K	15 Mar 2013	2012	FY
Q3 2010		$1,519,000			01 Jul 2010	30 Sep 2010	10-Q	08 Nov 2011	2011	Q3
Q2 2010		$2,091,000			01 Apr 2010	30 Jun 2010	10-Q	09 Aug 2011	2011	Q2

PLUS THERAPEUTICS, INC. Annual Revenues (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$5,824,000	+$911,000	+19%	01 Jan 2024	31 Dec 2024	10-K	31 Mar 2025	2024	FY
2023	$4,913,000			01 Jan 2023	31 Dec 2023	10-K	31 Mar 2025	2024	FY
2017	$2,689,000	-$1,967,000	-42%	01 Jan 2017	31 Dec 2017	10-K	09 Mar 2018	2017	FY
2016	$4,656,000	-$182,000	-3.8%	01 Jan 2016	31 Dec 2016	10-K	09 Mar 2018	2017	FY
2015	$4,838,000	-$115,000	-2.3%	01 Jan 2015	31 Dec 2015	10-K	24 Mar 2017	2016	FY
2014	$4,953,000	-$2,169,000	-30%	01 Jan 2014	31 Dec 2014	10-K	11 Mar 2016	2015	FY
2013	$7,122,000	-$1,587,000	-18%	01 Jan 2013	31 Dec 2013	10-K	11 Mar 2016	2015	FY
2012	$8,709,000	+$726,000	+9.1%	01 Jan 2012	31 Dec 2012	10-K	16 Mar 2015	2014	FY
2011	$7,983,000	-$271,000	-3.3%	01 Jan 2011	31 Dec 2011	10-K	14 Mar 2014	2013	FY
2010	$8,254,000			01 Jan 2010	31 Dec 2010	10-K	15 Mar 2013	2012	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.